258
Participants
Start Date
January 25, 2021
Primary Completion Date
September 13, 2027
Study Completion Date
April 20, 2028
Isatuximab
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
Dexamethasone
Pharmaceutical form: Tablet; Route of administration: Oral
Pomalidomide
Pharmaceutical form: Capsule; Route of administration: Oral
Belantamab mafodotin
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Pegenzileukin
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
SAR439459
Pharmaceutical form: Solution for injection; Route of administration: Intravenous
Belumosudil
Pharmaceutical form: tablet; route of administration: oral
Evorpacept
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
RECRUITING
Investigational Site Number : 0360006, Wollongong
RECRUITING
Investigational Site Number : 0360002, Melbourne
RECRUITING
Investigational Site Number : 0360001, Richmond
RECRUITING
Roswell Park Cancer Institute- Site Number : 8400008, Buffalo
RECRUITING
Investigational Site Number : 2760008, Lübeck
RECRUITING
Investigational Site Number : 2500001, Nantes
RECRUITING
Investigational Site Number : 3800001, Meldola
RECRUITING
University of Michigan Health System - Ann Arbor- Site Number : 8400004, Ann Arbor
RECRUITING
Investigational Site Number : 2500002, Lille
RECRUITING
Investigational Site Number : 2760006, Frankfurt
COMPLETED
University of Illinois-Chicago - College of Medicine- Site Number : 8400007, Chicago
RECRUITING
Investigational Site Number : 2500004, Paris
RECRUITING
Investigational Site Number : 2500003, Paris
RECRUITING
Investigational Site Number : 3760003, Ramat Gan
RECRUITING
Investigational Site Number : 3760001, Tel Aviv
RECRUITING
Investigational Site Number : 3760002, Jerusalem
RECRUITING
Winship Cancer Institute, Emory University- Site Number : 8400010, Atlanta
RECRUITING
Investigational Site Number : 3000002, Athens
RECRUITING
Investigational Site Number : 3000001, Athens
RECRUITING
Investigational Site Number : 5780001, Oslo
RECRUITING
Investigational Site Number : 6200001, Coimbra
RECRUITING
Investigational Site Number : 6200002, Porto
RECRUITING
Puerto Rico Medical Research Center- Site Number : 8400005, HATO REY
RECRUITING
Investigational Site Number : 4100004, Seoul
RECRUITING
Investigational Site Number : 4100002, Seoul
RECRUITING
Investigational Site Number : 4100003, Seoul
RECRUITING
Investigational Site Number : 4100001, Seoul
Lead Sponsor
Sanofi
INDUSTRY